Activation of the innate immune system is an initial response of the body to infection and injury. The resulting inflammation aims to protect against stressors and restore tissue and organism homeostasis. This process is driven largely by IL-1β, one of the first cytokines described 1 . However, prolonged activation of the immune system by over-nutrition can eventually promote the development of metabolic diseases [2] [3] [4] [5] [6] . A critical sensor of nutrient overload is the NLRP3 inflammasome, which processes pro-IL-1β into its active form in various metabolic disorders. This is the case for uric acid crystals, which activate the NLRP3 inflammasome in gout 7 ; for cholesterol crystals in atherogenesis 8 ; and for glucose, fatty acids and islet amyloid polypeptide in type 2 diabetes 9-13 . Notably, a causal link between IL-1β-induced inflammation and those metabolic diseases has been demonstrated by various genetic and pharmacological approaches in animal models [14] [15] [16] and in clinical trials [17] [18] [19] [20] [21] . While such studies have shed light on the pathological role of IL-1β in metabolism, a physiological function for IL-1β in metabolic control has remained largely unexplored.
Activation of the innate immune system is an initial response of the body to infection and injury. The resulting inflammation aims to protect against stressors and restore tissue and organism homeostasis. This process is driven largely by IL-1β, one of the first cytokines described 1 . However, prolonged activation of the immune system by over-nutrition can eventually promote the development of metabolic diseases [2] [3] [4] [5] [6] . A critical sensor of nutrient overload is the NLRP3 inflammasome, which processes pro-IL-1β into its active form in various metabolic disorders. This is the case for uric acid crystals, which activate the NLRP3 inflammasome in gout 7 ; for cholesterol crystals in atherogenesis 8 ; and for glucose, fatty acids and islet amyloid polypeptide in type 2 diabetes [9] [10] [11] [12] [13] . Notably, a causal link between IL-1β-induced inflammation and those metabolic diseases has been demonstrated by various genetic and pharmacological approaches in animal models [14] [15] [16] and in clinical trials [17] [18] [19] [20] [21] . While such studies have shed light on the pathological role of IL-1β in metabolism, a physiological function for IL-1β in metabolic control has remained largely unexplored.
In response to pathogens and obesity, profound changes in the metabolism of immune cells take place [22] [23] [24] [25] . Beyond supplying energy, nutrients can also act as signaling molecules that promote the activation of immune cells. Indeed, elevated concentrations of glucose and other metabolites drive production of IL-1β by macrophages 14, 26 .
Insulin-producing pancreatic β-cells have the highest expression of the IL-1 receptor of any tissue 27 , and the IL-1 receptor is the most abundantly expressed cell-surface receptor on β-cells 28 , indicative of a previously unappreciated physiological function. While the deleterious role of high-dose and long-term exposure to IL-1β on islet function and mass is well documented 29, 30 , a few, mainly in vitro, observations have hinted at a possible beneficial role for IL-1β in insulin secretion and β-cell survival 31, 32 .
Parenteral stimulation with glucose leads to a rapid first and second phase of insulin release. In contrast, the physiological slower resorption of a meal elicits a sustained increase in insulin that depends on the duration of food intake 33 . However, the insulin response to enteral food intake cannot be accounted for solely by the associated changes in blood glucose. It is modulated by several insulin secretagogues, including the incretin hormones GLP-1 and GIP 34 . These hormones promote insulin secretion only when glucose levels are elevated. While GIP and GLP-1 are the best-described incretins, other incretin-like factors are thought to exist.
A r t i c l e s
Several studies have shown that food intake transiently induces a mild inflammatory response 35, 36 . We hypothesized that IL-1β contributes to this postprandial inflammation, regulating whole-body glucose homeostasis along with an innate immune response. It might thereby deliver the energy needed to activate the innate immune system to prevent the dissemination of microorganisms contained in the food. We found here that a postprandial increase in glucose led to an acute elevation in macrophage-derived IL-1β, which contributed to postprandial insulin secretion via the abundantly expressed IL-1 receptor on β-cells. Insulin reinforced a pro-inflammatory state and stimulated macrophages to produce IL-1β via glucose metabolism and the subsequent production of reactive oxygen species (ROS), which lead to activation of the inflammasome 14, 37 . Both insulin and IL-1β regulated the disposal of glucose, whereas IL-1β 'preferentially' stimulated the uptake of glucose into the immune-cell compartment.
RESULTS

Feeding stimulates intraperitoneal macrophages to produce IL-1
To study the physiological involvement of IL-1β in insulin secretion, we performed experiments in which wild-type mice and IL-1β-deficient (Il1b −/− ) mice underwent overnight fasting, followed by refeeding. At 2 h after the start of refeeding, the circulating IL-1β concentration was increased (relative to the concentration after fasting but before refeeding) only in wild-type mice, while, as expected, IL-1β was undetectable in Il1b −/− mice ( Fig. 1a; validation assay, Supplementary Fig. 1a ). Of note, in wild-type mice, the concentration of IL-1β in serum was already elevated at 30 min after the start of refeeding (data not shown).
Next we investigated the source of the increased IL-1β. At 2 h after the start of refeeding, the expression of Il1b mRNA and of mRNA encoding the IL-1β-dependent chemokines CXCL1 and CCL2 was greater in the omental fat (the main site from which macrophages migrate into the peritoneum 38, 39 ) of mice that had undergone fasting and refeeding than in that of mice that had undergone prolonged fasting (Fig. 1b) but not in the circulating leukocytes, liver, spleen, epididymal fat or subcutaneous fat (data not shown). Furthermore, the number of stromal vascular cells isolated from the omentum was reduced from 41.8 × 10 3 ± 13.4 × 10 3 cells per mg tissue (after fasting) to 8.3 × 10 3 ± 2.6 × 10 3 cells per mg tissue (after refeeding) (mean ± s.e.m.). Accordingly, we isolated many more peritoneal cells from mice that had undergone fasting and refeeding than from those that had undergone fasting alone (Fig. 1c) ; the former also displayed higher expression of Il1b mRNA (Fig. 1d) . Flow cytometry revealed that the majority of those cells were macrophages ( Fig. 1e; gating strategy, Supplementary Fig. 1b ) and that this distribution remained unchanged between fasting and refeeding (data not shown). Ex vivo, spontaneous release of IL-1β by cultured peritoneal macrophages after fasting was comparable to that after refeeding (data not shown). However, macrophages obtained from mice after refeeding released more IL-1β following stimulation with ATP (Fig. 1f) . To confirm the source of the increased IL-1β during refeeding, we generated Il1b fl/fl Lyz2-Cre mice (with loxP-flanked Il1b alleles (Il1b fl/fl ) deleted by Cre recombinase expressed from the myeloid-compartment-specific gene Lyz2), which specifically lack IL-1β in the myeloid lineage (Supplementary Fig. 1c) . The circulating IL-1β concentration was increased at 2 h after refeeding in the Il1b fl/fl mice but not in their Il1b fl/fl Lyz2-Cre littermates (Fig. 1g) .
We then investigated whether the increase in serum glucose following feeding mediated the postprandial increase in IL-1β. We treated mice with the SGLT2 inhibitor canagliflozin, which diminishes glycemia via inhibition of renal glucose reabsorption. Treatment of wild-type mice with canagliflozin induced glycosuria and prevented the postprandial increase in glucose and insulin ( Supplementary Fig. 1d-f) , along with complete prevention of the postprandial increase in circulating IL-1β (Fig. 1h) . Similarly, injection of the glucose analog 2-deoxyglucose (2DG), which cannot be metabolized, before refeeding substantially diminished the release of IL-1β (Fig. 1i) .
Finally, we assessed the role of bacterial products in the stimulation of postprandial IL-1β by treating mice with broad-spectrum antibiotics or lipopolysaccharide (LPS). Mice treated with antibiotics tended to have milder postprandial inflammation than that of untreated mice, as assessed by expression of Il1b and Cxcl1 in the omental fat pad (Supplementary Fig. 1g,h) , together with slightly lower postprandial circulating IL-1β concentrations (Supplementary Fig. 1i) , despite similar food intake in these mice and no change in the number of peritoneal cells (Supplementary Fig. 1j-l) . Ex vivo, peritoneal macrophages from mice treated with antibiotics released less IL-1β, even in the presence of ATP, than did those from untreated mice (Fig. 1j) . However, ex vivo priming of those cells with LPS before ATP stimulation restored IL-1β secretion to that observed in cells obtained from untreated mice (Fig. 1j) . Accordingly, in vivo intraperitoneal injection of LPS into mice that had not undergone fasting increased their circulating IL-1β concentration along with that of insulin and decreased the concentration of glucose in blood (Fig. 1k) . Unlike results obtained for wild-type mice, injection of LPS into Il1b −/− mice) failed to induce insulin (Fig. 1l) . This suggested a need for a microberelated stimulus and energy supply (glucose) in the induction of the postprandial release of IL-1β. Thus, feeding increased the number of intraperitoneal macrophages, which were primed by bacterial products to produce and release IL-1β in response to glucose.
Postprandial macrophage IL-1 promotes insulin secretion Next we assessed the direct effect of elevated IL-1β on insulin secretion, after refeeding. First, we measured postprandial circulating insulin in Il1b −/− and wild-type littermates after refeeding. The Il1b −/− mice had reduced secretion of insulin (Fig. 2a) and elevated blood glucose ( Supplementary Fig. 2a ) after refeeding relative to that of their wild-type littermates, despite comparable food intake in these mice (data not shown). Since the number of peritoneal cells was increased after refeeding (Fig. 1c) , and macrophages were the most abundant immune cells in the peritoneal cavity (Fig. 1e) , we depleted wild-type mice of macrophages by intraperitoneal injection of clodronate liposomes ( Supplementary Fig. 2b ) before performing fasting-refeeding experiments. Depletion of macrophages resulted in much lower postprandial insulin in the circulation than that of mice that received empty liposomes (Fig. 2b) . Similarly, postprandial insulin was lower in Il1b fl/fl Lyz2-Cre mice than in their Il1b fl/fl littermates (Fig. 2c) . In addition, acute blockade of IL-1 with its natural antagonist IL-1Ra before refeeding resulted in slightly lower circulating insulin concentrations in wild-type mice (Fig. 2d) and higher blood glucose ( Supplementary  Fig. 2c ) than that of mice given saline. Since obesity is associated with inflammation and chronically elevated IL-1β and insulin 9 , we investigated the effect of acute antagonism of IL-1 (1 h before refeeding) in mice with diet-induced obesity ('DIO mice') to substantiate the ability of endogenous IL-1β to regulate insulin. Circulating IL-1β concentrations were elevated in DIO mice (Fig. 2e) , and blocking IL-1 with IL-1Ra lowered fasting insulin concentrations in DIO mice relative to that of their saline-treated counterparts (Fig. 2f) without changing sensitivity to insulin or the hepatic production of glucose, as determined with a hyperinsulinemic-euglycemic clamp (Fig. 2g,h) . As a second model, we injected IL-1Ra into db/db mice, which have a genetic form of obesity (deficiency in the leptin receptor), and found that this also decreased insulin concentrations (Fig. 2i) . Therefore, postprandial IL-1β derived from myeloid cells promoted the secretion of insulin.
Acute exposure to IL-1 induces insulin secretion To directly test the effect of IL-1β on insulin secretion in vivo, we gave mice acute injection of IL-1β, followed by an intraperitoneal glucose tolerance test (GTT). Such injection of IL-1β led to much greater insulin secretion (Fig. 3a) and improved glucose tolerance (Fig. 3b) relative to that of mice given injection of saline. Insulin was also increased and glycemia was improved by such administration of IL-1β in the absence of a glucose bolus, but to a much lesser extent (Fig. 3c,d) . Such glucose-dependent potentiation of insulin secretion is reminiscent of effects elicited by the incretin hormones GLP-1 and GIP 34 . However, the concentration of circulating active GLP-1 remained unchanged following injections of IL-1β ( Supplementary  Fig. 3a) . Furthermore, the effect of IL-1β on insulin secretion and glucose tolerance was identical in mice deficient in both the receptor for GLP-1 and the receptor for GIP (Glp1r −/− Gipr −/− mice) and their wild-type littermates (Supplementary Fig. 3b,c) , and treatment of wild-type mice with a GLP-1 inhibitor (exendin fragment 9-39) did not diminish the effect of IL-1β on insulin secretion (data not shown). Therefore, IL-1β did not promote glucose-induced secretion of insulin via incretin hormones. Since insulin secretion could be increased as a result of IL-1β-mediated peripheral resistance to insulin, we used insulin-tolerance tests and hyperinsulinemic-euglycemic clamp studies to determine if insulin sensitivity changed after acute injection of IL-1β. Acute injection of IL-1β had no effect on insulin sensitivity or hepatic glucose production ( Fig. 3e and Supplementary Fig. 3d ). (pg/ml)
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(ng/ml) A r t i c l e s IL-1β also improved glucose tolerance and substantially increased insulin secretion in DIO mice (Fig. 3f,g ) and in db/db mice ( Fig. 3h,i ), relative to that of DIO mice or db/db mice treated with saline. In contrast to their wild-type counterparts, mice deficient in the IL-1-receptor-associated kinase IRAK4 (Irak4 −/− mice) showed no improvement in insulin secretion or in glycemia after injection of IL-1β followed by an intraperitoneal GTT ( Supplementary Fig. 3e,f) ; this demonstrated that the observed effects of IL-1β were mediated by the IL-1 receptor signal-transduction pathways. Of note, intraperitoneal injection of IL-1β into wild-type mice at a dose of 0.1 µg per kg body weight resulted in circulating IL-1β concentrations similar to those obtained after refeeding, and it also induced insulin secretion (Fig. 3j,k) . Next we investigated whether LPS had effects similar to those reported above. Acute intraperitoneal injection of LPS improved glucose tolerance and increased insulin secretion in both wild-type mice and DIO mice (Fig. 4a,b) , relative to results obtained with saline. Notably, treatment with IL-1Ra blocked the LPS-induced insulin secretion in wild-type mice (Fig. 4c) . There was much higher expression of mRNA encoding the type 1 IL-1 receptor (IL-1R1) in isolated endocrine cells than in islet-resident immune cells or endothelial cells in wild-type mice (Fig. 4d) . Specific immunostaining of wild-type mouse pancreatic tissue sections revealed the presence of IL-1R1 in a subpopulation of β-cells (Fig. 4e) .
Published in vitro studies 32 have demonstrated that very low concentrations of IL-1β enhance the glucose-stimulated secretion of insulin from islets. We confirmed that effect in mouse and human islets and with the human β-cell line ENDOC (Supplementary Fig. 3g-i) , which suggested a direct β-cell effect. To determine whether acute administration of IL-1β in vivo would act directly on the islet, we used streptozotocin to eliminate β-cells in immunodeficient recipient mice, followed by transplantation of islets from wild-type or IL-1R1-deficient (Il1r1 −/− ) donor mice. The effect of IL-1β on insulin secretion and glucose tolerance was lost in mice given transplantation of islets from Il1r1 −/− mice (Fig. 4f,g ). These results suggested that systemic IL-1β potentiated glucose-induced secretion of insulin via islet IL-1R1 and that this was independent of the incretins GLP-1 and GIP or of changes in insulin resistance.
Insulin stimulates IL-1 secretion by macrophages
Since IL-1β enhanced insulin secretion during refeeding, we investigated the possible synergistic contribution of insulin and IL-1β to the stimulation of the immune system. First, we investigated, by flow cytometry, expression of the insulin receptor (InsR) on resident macrophages isolated from various tissues. We found that peritoneal macrophages had the highest expression of InsR among all tissue-resident macrophages assessed (Fig. 5a) . Moreover, we found that InsR expression was upregulated in peritoneal macrophages from DIO mice relative to its expression in chow fed wild-type mice (Fig. 5b) , and it was upregulated in pro-inflammatory M1 macrophages, whereas it was slightly downregulated in anti-inflammatory M2 macrophages, relative to its expression in naive M0 macrophages ( Fig. 5c and Supplementary Fig. 4a) . Accordingly, insulin induced phosphorylation of the kinase AKT in naive M0 macrophages and induced it to A r t i c l e s a greater extent in M1 macrophages, but did not induce it in M2 macrophages ( Fig. 5d and Supplementary Fig. 4b ). The effect of insulin on AKT phosphorylation was confirmed by quantitative multiplex assay (Fig. 5e) . In contrast to its effect on the pathway for activation of the kinase PI(3)K, insulin had no effect on the phosphorylation of kinases of the MAPK family (JNK, p38 and ERK; Fig. 5f ). Insulin also stimulated upregulation of the gene encoding the glucose transporter GLUT1, the isoform expressed mainly in immune cells 25 (Fig. 5g) , and expression of the gene encoding hexokinase 2, the rate-limiting enzyme in glycolysis (Fig. 5h) , in M1 macrophages. In line with that pattern, 2 h of treatment with insulin increased glycolytic activity in M1 macrophages but not in naive or M2 macrophages ( Fig. 5i and Supplementary Fig. 4c ). In accordance with the results of the phosphorylation assay, the AKT-signaling inhibitor LY294002 blocked the effect of insulin on glycolytic activity in M1 macrophages, but the MAPK-signaling inhibitor U0126 did not (Fig. 5j) . Furthermore, insulin induced the uptake of glucose into naive macrophages, and this effect was enhanced by IL-1β (Fig. 5k) . Similar to the pattern of InsR expression and activation, insulin induced the secretion of IL-1β 'preferentially' by M1 macrophages in an NLRP3-dependent manner (Fig. 6a) . Insulin also stimulated expression of the genes encoding the cytokines TNF and IL-6 and the chemokine CXCL1 in M1 macrophages and release of those proteins from M1 macrophages, but it did so independently of activation of NLRP3 (Supplementary Fig. 4d,e) . This effect of insulin on IL-1β seemed to be independent of cell death and survival, which remained unaffected (Supplementary Fig. 4f ). Similar to insulin-induced glycolysis, insulin stimulated IL-1β via the PI(3)Kactivation pathway and was blocked by LY294002 and downstream by rapamycin, the inhibitor of the metabolic-checkpoint kinase mTOR (Fig. 6b) .
We then investigated the role of glucose metabolism in insulin-induced secretion of IL-1β. First, the GLUT1 inhibitor fasentin blocked IL-1β secretion (Fig. 6c) . In addition, insulin failed to induce IL-1β in cells cultured with 2DG (the glucose analog that cannot be metabolized) or with Mito-TEMPO (an ROS scavenger targeted to mitochondria) (Fig. 6d) . IL-1Ra was undetectable following short-term exposure (2 h) to insulin (data not shown); however, prolonged exposure (12 h) to insulin induced secretion of IL-1Ra from M0 and M1 macrophages (Fig. 6e) , which indicated that the induction of IL-1β (Fig. 6f) was later counterbalanced by secretion of IL-1Ra. Similar to our in vitro data, acute injection of insulin into (which encodes hexokinase 2) (h) in M0 and M1 macrophages (n = 9 biological replicates) treated for 2 h with insulin (1 µg/ml) or not (presented as in e,f). (i) Extracellular acidification rate (ECAR) of M1 macrophages incubated for 2 h in the presence (Insulin; n = 12 biological replicates) or absence (Control; n = 15 biological replicates) of insulin (1 µg/ml) (key), then given sequential injection of glucose, oligomycin, the mitochondrial uncoupler FCCP and electron-transport-chain inhibitor rotenone (vertical dotted lines; horizontal axis). (j) ECAR of M1 macrophages (n = 9 biological replicates) given mock injection (Control) or acutely treated with insulin (1 µg/ml) alone or with the inhibitor LY294002 (10 µM) or U0126 (10 µM) (vertical dotted lines indicate treatment start). (k) Glucose uptake in naive macrophages (Control; n = 21 biological replicates) or macrophages incubated for 3 h with insulin (1 µg/ml) alone (n = 28 biological replicates) or in combination with IL-1β (1 ng/ml) (n = 15 biological replicates). Each symbol (a-c,e-h,k) represents an individual mouse; small horizontal lines indicate the mean (± s.e.m.). *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0. mice increased the concentrations of circulating IL-1β and CXCL1 ( Fig. 6g and Supplementary Fig. 4g ). Overall, these data showed that insulin induced inflammasome-mediated secretion of IL-1β via enhanced glucose metabolism and mitochondrial ROS production. These effects were dependent on the PI(3)K-AKT pathway and on the activity status of the macrophages.
IL-1 shifts the uptake of glucose into immune cells
Next we investigated how IL-1β contributes to glucose disposal. Exposure of macrophages to IL-1β led to greater uptake of glucose than that of untreated control cells (Fig. 7a) , while blocking endogenously produced IL-1 with IL-1Ra resulted in less glucose uptake than that of untreated control cells (Fig. 7b) . We then assessed the effect of injection of IL-1β and insulin on glucose uptake in wild-type mice.
To avoid glucose-stimulated secretion of insulin, we only used trace amounts of radiolabeled glucose that cannot be metabolized. IL-1β stimulated glucose uptake in the spleen and circulating leukocytes (Fig. 7c,d) . IL-1β also increased glucose uptake in adipose tissue; however, it did so to a lesser extent than did insulin (Fig. 7e-g ). This might have been potentially due to the mild stimulation of insulin secretion by IL-1β observed in the absence of a glucose bolus (Fig. 3c) . To mimic chronic elevation of IL-1β, we gave mice daily injection of IL-1β for 3 consecutive days and assessed the number and glucose uptake of peritoneal cells. Similar to results obtained for mice after refeeding (Fig.  1c) , wild-type mice given injections of IL-1β had more peritoneal cells than did wild-type mice given injections of saline (Fig. 7h) . The ex vivo uptake of glucose by macrophages from mice given injections of IL-1β mice was greater than that of macrophages from mice given injections of saline (Fig. 7i) . To assess the physiological relevance of IL-1β-induced glucose uptake, we investigated postprandial glucose uptake in the immune cells of mice after refeeding. Blockade of endogenous IL-1 with IL-1Ra decreased the uptake of glucose into peritoneal macrophages relative to that of saline-treated cells (Fig. 7j) .
To further investigate the contribution of immune cells to overall glucose disposal, we first studied mice deficient in T cells and B cells (Rag2 −/− mice). A single injection of IL-1β before a GTT lowered glucose concentrations in Rag2 −/− mice as potently as it did in their Rag2 +/− (control) littermates (Supplementary Fig. 5a ). Since the T-cell-and B-cell-deficient Rag2 −/− mice have a compensatory increase in the number of macrophages, we additionally ablated macrophages in Rag2 −/− mice through the use of clodronate liposomes ( Supplementary  Fig. 5b ). This diminished the profound beneficial effect of IL-1β on glucose disposal, despite the higher concentration of insulin in these mice than in mice treated with empty liposomes (Fig. 7k) ; this suggested that immune cells contributed substantially to the IL-1β-induced disposal of glucose. Thus, in addition to the stimulation of insulin, IL-1β directly regulated glycemia by promoting glucose disposal 'preferentially' in immune cells (Supplementary Fig. 6 ).
DISCUSSION
In the present study we found that feeding induced a physiological elevation in macrophage-derived IL-1β that promoted postprandial insulin secretion. This effect depended on bacterial products, which primed macrophages to produce more pro-IL-1β, and on glucose, which drove the maturation of IL-1β. The production of IL-1β by M1 macrophages and, to a lesser extent, by M0 macrophages was enhanced by insulin. Insulin upregulated functional InsRs, signaling via the AKT-PI(3)K pathway, glucose uptake via the glucose transporter GLUT1, glucose metabolism, and ROS production that activates the NLRP3 inflammasome 14, 37 . Both insulin and IL-1β regulated whole-body glucose disposal by promoting glucose uptake in muscle and fat, and fueled the immune system by stimulating the uptake of A r t i c l e s glucose into the immune-cell compartment. Ablation of macrophages in T-cell-and B-cell-deficient Rag2 −/− mice significantly diminished the IL-1β-mediated clearance of glucose. Self-amplification of the system was limited by normalization of glycemia. The number of macrophages in the peritoneum was increased after refeeding, along with increased expression of genes encoding inflammatory molecules, including IL-1β in omental fat, which supports active trafficking of macrophages into the peritoneal cavity 40 . Therefore, feeding stimulated immunosurveillance, possibly to limit the dissemination of microorganisms contained in food. Activation of the immune system requires energy and contributes substantially to whole-body glucose consumption. We have provided evidence that both bacterial products and glucose metabolism were needed to induce the postprandial secretion of IL-1β by peritoneal macrophages. Indeed, we found that peritoneal cells from mice after refeeding had elevated expression of Il1b mRNA. This might have been promoted by the translocation of ingested or intestinal bacterial products rather than by the microbiota itself [41] [42] [43] , since pretreatment of mice with antibiotics before refeeding lowered IL-1β secretion only slightly. However, the stimulation of IL-1β release substantially depended on glucose uptake and metabolism. Indeed, we observed that diminishing glycemia via inhibition of SGLT2 or blocking glycolysis with 2DG prevented the elevation in postprandial IL-1β in the circulation in mice after refeeding. This suggested that among all the factors that might mediate this effect during feeding, such as mechanical stress of the digestive system, or intake of fiber, amino acids and fat, it was mainly glucose that drove the secretion of IL-1β. Our results also suggested a role for insulin in postprandial secretion of IL-1β, since insulin increased the uptake and metabolism of glucose in macrophages. Inhibiting glucose uptake with fasentin or 2DG blocked the insulin-induced secretion of IL-1β. Downstream, inhibiting mitochondrial ROS production, which activates the NLRP3 inflammasome 14, 37 , also prevented insulin from inducing IL-1β.
Published in vitro studies have shown that low concentrations of IL-1β mildly stimulate insulin secretion 32 . Here we found that in vivo, injection of IL-1β strongly potentiated insulin secretion in the presence of a glucose bolus. However, the most natural way to stimulate insulin secretion is eating. We showed that the IL-1β-induced release of insulin occurred physiologically by demonstrating that postprandially produced IL-1β increased insulin levels and decreased glycemia. This effect of IL-1β was mediated in part by the high expression of IL-1R1 on β-cells, since the effect of IL-1β on insulin secretion and glucose tolerance was blunted in diabetic mice given transplantation of islets from Il1r1 −/− mice.
The beneficial effects of postprandial IL-1β on glucose homeostasis were in apparent contrast to the glucose-lowering effects of IL-1 antagonism in patients with type 2 diabetes 17 and to the well-described deleterious effects of IL-1β on islet function and survival 4 . Although IL-1β elicits β-cell demise 30, 44 , at low concentrations or after short exposure, IL-1β paradoxically stimulates β-cell proliferation and decreases β-cell apoptosis 32 . Therefore, IL-1β not only is detrimental for β-cells but also has more-complex biological functions 45 . An explanation to reconcile the beneficial effects of IL-1 blockade in type 2 diabetes is the difference between acute effects and chronic effects and the concept of β-cell 'rest' . Indeed, potassium-channel openers, which decrease insulin secretion, ultimately improve insulin secretion in patients with type 2 diabetes 46 . The benefit of IL-1 antagonism in patients with type 2 diabetes might result from β-cell 'rest' , possibly in combination with inhibition of the toxic effects of IL-1β. A further explanation for the finding that chronic upregulation of IL-1β leading to elevated insulin levels might become unfavorable for metabolism stemmed from our observation that insulin reinforced the inflammatory state of macrophages through enhanced glucose uptake and metabolism and increased InsR expression in the macrophages of DIO mice. Indeed, activated macrophages have a crucial role in insulin resistance 47 . In line with that, InsR expression was also higher in macrophages from DIO mice, in which macrophages have been shown to be pro-inflammatory 6 . Thus, we propose that plasma insulin concentrations, which are increased in the early stages of type 2 diabetes, might drive and sustain the inflammatory state in macrophages and might therefore contribute to the chronic low-grade inflammation associated with metabolic diseases. Thereby, TNF, IL-6 and CXCL1 might also add to the effect of IL-1β. In support of that, mice with InsR deficiency restricted to myeloid cells are protected against metabolic inflammation and insulin resistance 48 .
The effect of insulin on macrophages has been studied without the polarization status of the macrophages being taken into account 49 . Here we found that insulin 'preferentially' acted on proinflammatory M1 macrophages characterized by more InsRs and, downstream, enhanced phosphorylation of AKT and glycolytic activity. Furthermore, insulin promoted the NLRP3 inflammasome and led to macrophage-derived release of IL-1β. Interestingly, peritoneal macrophages had the greatest density of InsRs, in support of the proposal of their contribution to postprandial homeostasis. SGLT2 inhibitors have been approved for the treatment of type 2 diabetes, and an outcome study (the Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes study) has revealed an impressive reduction in mortality in patients treated with the SGLT2 inhibitor empagliflozin 50 . However, the mechanisms that lead to this protective effect have remained unclear. In the present study, we found that canagliflozin prevented the postprandial elevation in IL-1β in the circulation. This could have been due to increased excretion of glucose into the urine, which would prevent an overload of glucose in tissues and thereby prevent the deleterious chronic effects of glucose-induced IL-1β.
Collectively, our findings have shown that IL-1β, a master regulator of inflammation, and insulin, a key hormone in glucose metabolism, promoted each other. Both had potent effects on glucose homeostasis and on the activity of the immune system, in support of the emerging concept that inflammatory mediators not only have a role in the pathology of metabolism but also are an integral part of its physiology. The physiological synergy between IL-1β and insulin in glucose disposal might be needed to cope with the concomitant challenge of nutrients and microorganisms related to food intake.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
